KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Raw Materials (2016 - 2022)

Historic Raw Materials for TherapeuticsMD (TXMD) over the last 11 years, with Q3 2022 value amounting to $1.9 million.

  • TherapeuticsMD's Raw Materials fell 4419.27% to $1.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.9 million, marking a year-over-year decrease of 4419.27%. This contributed to the annual value of $3.0 million for FY2021, which is 1883.67% down from last year.
  • TherapeuticsMD's Raw Materials amounted to $1.9 million in Q3 2022, which was down 4419.27% from $434000.0 recorded in Q2 2022.
  • In the past 5 years, TherapeuticsMD's Raw Materials ranged from a high of $5.7 million in Q4 2019 and a low of $19400.0 during Q4 2018
  • Moreover, its 5-year median value for Raw Materials was $3.5 million (2021), whereas its average is $2.9 million.
  • Per our database at Business Quant, TherapeuticsMD's Raw Materials skyrocketed by 2929044.85% in 2019 and then crashed by 9042.58% in 2022.
  • Over the past 5 years, TherapeuticsMD's Raw Materials (Quarter) stood at $19400.0 in 2018, then skyrocketed by 29290.45% to $5.7 million in 2019, then crashed by 34.27% to $3.7 million in 2020, then decreased by 18.84% to $3.0 million in 2021, then plummeted by 36.03% to $1.9 million in 2022.
  • Its Raw Materials was $1.9 million in Q3 2022, compared to $434000.0 in Q2 2022 and $4.4 million in Q1 2022.